← Back to Search

NMDA Receptor Antagonist

Ketamine for Obsessive-Compulsive Disorder (MKET Trial)

Phase 2

Waitlist Available

Led By Carolyn I Rodriguez, MD, PhD

Research Sponsored by Stanford University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

ages 18-65

capacity to provide informed consent

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 6 months

Awards & highlights

MKET Trial Summary

This trial will test how well ketamine works to reduce OCD symptoms compared to a placebo.

Who is the study for?

This trial is for adults aged 18-65 with a primary diagnosis of OCD who can give informed consent. Participants should have severe enough OCD symptoms to warrant the study and be able to go without other treatments for a while.Check my eligibility

What is being tested?

The study aims to understand how Ketamine, compared with Midazolam, can rapidly alleviate symptoms of OCD. Patients will receive one of these drugs and their effects on OCD improvement will be closely monitored.See study design

What are the potential side effects?

Ketamine may cause side effects like disorientation, blurred vision, dizziness, nausea, or increased blood pressure. Midazolam might lead to sleepiness, memory issues or coordination problems.

MKET Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 18 and 65 years old.

Select...

I understand and can agree to the study's procedures and risks.

Select...

My primary diagnosis is OCD.

Select...

I am between 18 and 65 years old.

MKET Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

improvement in the severity of OCD symptoms as measured by the Yale-Brown Obsessive Compulsive Scale (YBOCS)

Secondary outcome measures

Regional gamma-aminobutyric acid, glutamate/glutamine levels derived from 3T Magnetic Resonance Spectroscopy

MKET Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: KetamineExperimental Treatment1 Intervention

OCD patients in this arm will receive 0.5mg/kg of ketamine - one single infusion

Group II: MidazolamActive Control1 Intervention

OCD patients in this arm will receive 0.045mg/kg of midazolam - one single infusion

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Ketamine

2011

Completed Phase 4

~1090

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor

2,386 Previous Clinical Trials

17,333,888 Total Patients Enrolled

15 Trials studying Obsessive-Compulsive Disorder

1,283 Patients Enrolled for Obsessive-Compulsive Disorder

University of ConnecticutOTHER

181 Previous Clinical Trials

157,925 Total Patients Enrolled

Carolyn I Rodriguez, MD, PhDPrincipal InvestigatorStanford University

3 Previous Clinical Trials

34 Total Patients Enrolled

1 Trials studying Obsessive-Compulsive Disorder

7 Patients Enrolled for Obsessive-Compulsive Disorder

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what ailments is Ketamine typically applied?

"Ketamine is a well-known treatment for seizures and epilepsy, but it can also ameliorate the symptoms of amnesia and be employed in certain therapeutic processes."

Answered by AI

Are any openings currently available for the trial's participants?

"Unfortunately, no longer are individuals being accepted for this trial. The posting date of June 1st 2016 and last update on May 24th 2022 indicate that recruitment has ceased; however, there are currently 114 active clinical trials involving patients with obsessive-compulsive disorder and 153 studies actively recruiting participants to test Ketamine's efficacy."

Answered by AI

How many patients have been enrolled for participation in this experiment?

"Currently, this study is not accepting patients. Initially posted on June 1st 2016 and final edited May 24th 2022, no further submissions are being accepted at the moment. However, there are 114 medical studies recruiting for all individuals with obsessive-compulsive disorder and another 153 clinical trials searching for suitable candidates to test Ketamine's efficacy."

Answered by AI

Is there an age limit for enrollees in this investigation?

"The age restrictions for participation in this clinical trial are clear. Participants must be above the legal age of consent and not exceed 65 years old."

Answered by AI

Is Ketamine associated with any hazardous effects?

"Ketamine's safety has been established to some degree, so it is given a score of 2. Despite this, there is no evidence that the drug can be effective in treating any conditions yet."

Answered by AI

To whom is participation in this trial available?

"In order to be accepted into this clinical trial, candidates must present with obsessive-compulsive disorder and lie within the age range of 18 - 65. The study is currently seeking 120 participants."

Answered by AI

Who else is applying?

What state do they live in?

Manitoba

California

Washington

Other

How old are they?

18 - 65

What site did they apply to?

Stanford University

What portion of applicants met pre-screening criteria?

Did not meet criteria

Met criteria

Why did patients apply to this trial?

Hi! I’ve tried countless medications and I’m currently on 2 that I’d rather not be on- gabapentin and Zoloft generic. I’ve heard great things about alternative treatments such as ketamine treatment for ocd.

PatientReceived 1 prior treatment